GB9926529D0 - Targeting agents - Google Patents

Targeting agents

Info

Publication number
GB9926529D0
GB9926529D0 GBGB9926529.0A GB9926529A GB9926529D0 GB 9926529 D0 GB9926529 D0 GB 9926529D0 GB 9926529 A GB9926529 A GB 9926529A GB 9926529 D0 GB9926529 D0 GB 9926529D0
Authority
GB
United Kingdom
Prior art keywords
targeting agents
targeting
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9926529.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KS Biomedix Ltd
Original Assignee
KS Biomedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KS Biomedix Ltd filed Critical KS Biomedix Ltd
Priority to GBGB9926529.0A priority Critical patent/GB9926529D0/en
Publication of GB9926529D0 publication Critical patent/GB9926529D0/en
Priority to AU11640/01A priority patent/AU1164001A/en
Priority to EP00973090A priority patent/EP1230270A1/en
Priority to JP2001537362A priority patent/JP2003513985A/en
Priority to CA002389386A priority patent/CA2389386A1/en
Priority to PCT/GB2000/004279 priority patent/WO2001034651A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB9926529.0A 1999-11-09 1999-11-09 Targeting agents Ceased GB9926529D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9926529.0A GB9926529D0 (en) 1999-11-09 1999-11-09 Targeting agents
AU11640/01A AU1164001A (en) 1999-11-09 2000-11-08 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their useas targeting agents
EP00973090A EP1230270A1 (en) 1999-11-09 2000-11-08 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents
JP2001537362A JP2003513985A (en) 1999-11-09 2000-11-08 Antibodies that bind non-naturally occurring enantiomers (L-biotin) and the use of such antibodies as targeting agents
CA002389386A CA2389386A1 (en) 1999-11-09 2000-11-08 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents
PCT/GB2000/004279 WO2001034651A1 (en) 1999-11-09 2000-11-08 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9926529.0A GB9926529D0 (en) 1999-11-09 1999-11-09 Targeting agents

Publications (1)

Publication Number Publication Date
GB9926529D0 true GB9926529D0 (en) 2000-01-12

Family

ID=10864231

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9926529.0A Ceased GB9926529D0 (en) 1999-11-09 1999-11-09 Targeting agents

Country Status (6)

Country Link
EP (1) EP1230270A1 (en)
JP (1) JP2003513985A (en)
AU (1) AU1164001A (en)
CA (1) CA2389386A1 (en)
GB (1) GB9926529D0 (en)
WO (1) WO2001034651A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870180A1 (en) * 2012-07-04 2015-05-13 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
BR112014029403A2 (en) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugates, antibody and pharmaceutical formulation
ES2600154T3 (en) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
CN105899540B (en) 2014-01-03 2020-02-07 豪夫迈·罗氏有限公司 Bispecific anti-hapten/anti-blood-brain barrier receptor antibodies, complexes thereof and their use as blood-brain barrier shuttles
CN105873615B (en) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
RU2682754C2 (en) 2014-01-03 2019-03-21 Ф. Хоффманн-Ля Рош Аг Covalent bonded polypeptide toxin and antibody conjugates
MX2016015280A (en) 2014-06-26 2017-03-03 Hoffmann La Roche Anti-brdu antibodies and methods of use.
WO2018122205A2 (en) * 2016-12-27 2018-07-05 F. Hoffmann-La Roche Ag Novel biotin-specific monoclonal antibody and use thereof
JP6901562B2 (en) * 2016-12-27 2021-07-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ New biotin-specific monoclonal antibody and its use
CN111171154B (en) * 2020-02-25 2021-05-11 杭州百凌生物科技有限公司 Anti-biotin antibody and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248611A (en) * 1987-05-28 1993-09-28 Scripps Clinic And Research Foundation Stereoisomer separation method using antibody combing site-containing molecules
US5190865A (en) * 1988-11-18 1993-03-02 The Regents Of The University Of California Antibody-enhanced stereospecific hydrolyses

Also Published As

Publication number Publication date
CA2389386A1 (en) 2001-05-17
JP2003513985A (en) 2003-04-15
EP1230270A1 (en) 2002-08-14
AU1164001A (en) 2001-06-06
WO2001034651A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
GB9911863D0 (en) Therapeutic agents
GB9905010D0 (en) Therapeutic agents
PL362904A1 (en) N-aryl-uracile-based herbicides
IL150030A0 (en) Therapeutic agents
GB9904786D0 (en) Therapeutic agents
GB9929685D0 (en) Therapeutic agents
GB9929687D0 (en) Therapeutic agents
GB9911881D0 (en) Therapeutic agents
GB9921351D0 (en) Therapeutic agents
GB9926529D0 (en) Targeting agents
GB9903476D0 (en) Therapeutic agents
GB9929569D0 (en) Therapeutic agents
HK1047241A1 (en) Radioprotecting agent
DE60044882D1 (en) Ie
GB9914744D0 (en) Therapeutic agents
GB9903119D0 (en) Therapeutic agents
GB9914742D0 (en) Therapeutic agents
GB9914745D0 (en) Therapeutic agents
GB9902881D0 (en) Therapeutic agents
GB9914743D0 (en) Therapeutic agents
GB9911792D0 (en) Herbicides
GB9915616D0 (en) Therapeutic agents
AU140373S (en) Bumbag
GB9915617D0 (en) Therapeutic agents
GB9918057D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)